RADIOPHARMA SOLUTIONS NEWSLETTER N°27- SUMMER 2021





The first two units of the Cyclone® June 10th 2021 marked the unveiling the coproduction of other isotopic of IBA's new versatile, high-energy impurities and therefore ensure the IKON have already been acquired

IBA LAUNCHES VERSATILE HIGH-ENERGY NEW CYCLOTRON

cyclotron, Cyclone® IKON! It was showcased during a virtual live event. If you missed it, no worries, you

can watch the replay here, you will have the opportunity to meet IKE, the soul of Cyclone® IKON!



and reduced radiopharmacy footprint. **Productive** Light & compact, the Cyclone® IKON makes no compromise on power with

up to 1500µA extracted beam current.

Adaptive

Injecting a pure and safe radiopharmaceutical is crucial. The optimization of the reaction energy is a key-factor in ensuring this is the case. Some very promising radioisotopes such as ⁶⁴Cu and ⁸⁹Zr are actually produced at energies of 13MeV to avoid

Cyclone® IKON offers the largest energy spectrum for PET and SPECT isotopes from 13 MeV to 30 MeV.

highest purity of the end-product.

Effective IBA is dedicated to support its

customers with radiopharmacy design, equipment integration, training &

production solutions from the target irradiation system all the way up to purified end-product. In this way, our customers have full control of their production process and know who to address for support. Watch the video to know more about the Cyclone® IKON:

GMP guidance. IBA offers complete

the reliability of its equipment. It has the most compact and

Visit our webiste for more info about

the Cyclone® IKON.

radiopharmaceuticals production! IBA has been a trusted partner of Curium for a long time. We selected IBA for its globally

recognized expertise and due to

by two leading companies in

the outstanding capabilities and reliability of the Cyclotron. Renaud Dehareng, **CEO of Curium Pharma**



efficient high energy cyclotron on the market. Erich Kollegger, CEO of IRE



RIGGING OF

RHODOTRON® AT NORTHSTAR MEDICAL RADIOISOTOPES

Two IBA Rhodotron®TT 300-HE (High Energy) electron beam accelerators were rigged in Beloit, Wisconsin. The

accelerators are critical components in a first-of-its-kind commercial-scale

process to produce Mo-99, the parent

radioisotope of technetium-99m, the most widely used medical imaging

radioisotope, informing healthcare decisions for approximately 40,000

U.S. patients daily.

AUSTRALIA

SUCCESS STORIES






Shortly IBA's Germanium and Iodine target/chemistry systems will be added on that machine to provide an effective oncology solution for the US market.

CYCLONE® KIUBE RIGGINGS AROUND THE WORLD

PRINCE OF SONGKLA ROYAL DARWIN HOSPITAL IN **UNIVERSITY (PSU) IN CHINA**



The cyclotron was successfully rigged at the PSU! The project offered jointly by


the establishment of a cutting edge GMP radiopharmaceutical production centers. The new PET center will produce various molecules including FDG and ⁶⁸Ga-PSMA on the Synthera®+ platform but also ¹³N, ¹¹C and ¹⁵O compounds!




patient diagnosis.

GUANGDONG SINOTAU MOLECULAR IMAGING TECHNOLOGY CO., LTD IN CHINA The cyclotron was rigged at Guangdong SinoTau Molecular Imaging Technology Co., Ltd. The new radiophamacy is equipped with cutting edge technology; the Cyclone® KIUBE Custom Energy and Synthera®+

synthesizers to ensure a reliable





production of ¹⁸F and ⁶⁸Ga tracers as well as ⁸⁹Zr and ⁶⁴Cu on solid target.

CHEMISTRY eSRS SATELLITE SYMPOSIUM FROM NEW TRACERS DEVELOPMENTS TO ROUTINE CLINICAL APPLICATIONS ON SYNTHERA® + PLATFORM

PET modality is one of the most rapidly growing area of medical imaging thanks to the availability of innumerous clinical centers with their own cyclotrons. To

be able to cover the growing clinical demands, radiopharmacies are developing

new tracers while keeping up their routine production in a [c]GMP environment.

In this symposium, Dr. Ida Nymann Petersen, PhD. and Dr. Vasko Kramer, PhD. shared their experience in the development of new tracers on the Synthera®

© 2021 IBA SA

IBA REINFORCES ITS RADIOCHEMISTRY TEAM!

eSRS Satellite Syn posiur

From new tracers development

Synthera® + platform

May 20th

radiochemist.


68Ga

CYCLOTRON

IBA's experts.

platform. Did you miss it? Watch the recording

of our radiochemistry team!



CLOSER TO THE USERS

oroutine clinical applications on

RADIO

PHARMA SOLUTIONS

lba

CMI. Inc CMI, Inc in Kyoto, Japan will now be able to produce FBB with their new Synthera®+ and Synthera®+ HPLC

INSTALLATIONS

SYNTHERA®

platforms.

Invicro

AROUND THE GLOBE

St. Teresa Hospital Hong Kong


St. Teresa Hospital Hong Kong

in Taiwan is now equipped with

the Synthera®+ platform with its loader and Synthera®+ HPLC for the production of FDG, NaF and FPSMA.

A Synthera® + with Loader and a Synthera® + HPLC have been installed at Invicro in London, UK. The synthesis modules will be dedicated to the

production of FBB for brain imaging.



Given the increased demand on Ga-68, IBA organized a special session for its users on June 24th 2.30pm (CET). A presentation about "68Ga production process from a cyclotron: why & how?" easier to share your recipes with the

SPECIAL IBA USERS SESSION ON 68 Ga PRODUCTION ON A

from Francisco Alves, chief physicist & head of cyclotron at ICNAS-University

of Coimbra in Portugal will be followed by 1 hour of discussion and Q&A with

For more information: radiopharmasolutions@iba-group.com

IBA WEBINARS

IBA redesigned the Synthera® library of compounds to make it even

Discover the new platform and upload your recipes: synthera-

<u>libraryofcompounds.com</u>

A NEW SYNTHERA® LIBRARY

OF COMPOUNDS

community!



Diagnostic efficacy of 68Ga-PSMA versus conventional imaging in prostate cancer patients. - By Dr. Jeremie Calais Watch it here

⁶⁸Ga-PSMA, from production to clinical applications

⁶⁸Ga Production process from a cyclotron: why & how?

Li Chen

Prof. Fancisco Alves

Chief physicist & head of Cyclotron at ICNAS-University

-By Prof. Francisco Alves

Körber "Quality assurance for SBRT treatments" - By Dr. Kai Schubert

iba-RadiopharmaSolutions.com

Belgium Tél.: +32 10 201 275 **Robert Kwizera Mugabo** Sales Area Manager EMEA Fax: + 32 10 47 59 00 Robert.KwizeraMugabo@iba-group.com RadioPharmaSolutions@iba-group.com

Chen.Li@iba-group.com Claudia Ochoa Vice President Western Europe &

Peter.Leitner@iba-group.com

Global Chemistry Solutions Claudia.Ochoa@iba-group.com Peter Leitner

Vice President APAC

Sales Director China

Dmitry Cherkasov Sales&Marketing Director Russia&CIS

RADIO **PHARMA**


SOLUTIONS



Dr. Jeremie Calais

WATCH OR REPLAY THE WEBINAR SERIE ON PSMA





the Management of Prostate Cancer



The Role of Specific PET PSMA Imaging and SBRT in

"Impact of PSMA PET on management of patients with oligo



Watch it here

Svlvain Savaria Ambrosio Moreno Vice President LATAM Vice President NA Ambrosio.Moreno@iba-group.com Sylvain.Savaria@iba-group.com

> <u>Dmitry.Cherkasov@iba-group.com</u> Sujala Vaniyath Chemistry Sales Manager

sujala.vaniyath@iba-group.com

IBA RadioPharma Solutions

Chemin du cyclotron, 3

1348 Louvain-la-Neuve